The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 175-180

  Feitosa, Mary F ^a   Wojczynski, Mary K ^a   North, Kari E ^b   Zhang, Qunyuan ^a   Province, Michael A ^a   Carr, Jeffrey J ^c   Borecki, Ingrid B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ALT; Correlated meta analysis; Genomewide association; Hepatic steatosis; Nonalcoholic fatty liver disease; Pleiotropic association

Indexed keywords

ALANINE AMINOTRANSFERASE; CHUK PROTEIN; CWF19L1 PROTEIN; ERLIN1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; FATTY LIVER; FEMALE; GENE CLUSTER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALANINE TRANSAMINASE; FATTY LIVER; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPATITIS; HUMANS; I-KAPPA B KINASE; MALE; MIDDLE AGED; MULTIGENE FAMILY; NERVE TISSUE PROTEINS; PHENOTYPE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84876785272     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.038     Document Type: Article

References (32)

1. Lewis J.R., Mohanty S.R. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010, 55:560-578.
2. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009, 48:1-26.
3. Schwenzer N.F., Springer F., Schraml C., Stefan N., Machann J., Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009, 51:433-445.
4. Boyce C.J., Pickhardt P.J., Kim D.H., et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 2010, 194:623-628.
5. Yamada J., Tomiyama H., Yambe M., et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis 2006, 189:198-205.
6. Schindhelm R.K., Diamant M., Dekker J.M., Tushuizen M.E., Teerlink T., Heine R.J. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006, 22:437-443.
7. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genomewide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7:e1001324.
8. Yuan X., Waterworth D., Perry J.R., et al. Population-based genomewide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008, 83:520-528.
9. Makkonen J., Pietiläinen K.H., Rissanen A., Kaprio J., Yki-Järvinen H. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 2009, 50:1035-1042.
10. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
11. Kotronen A., Johansson L.E., Johansson L.M., et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52:1056-1060.
12. Sookoian S., Castaño G.O., Burgueño A.L., Gianotti T.F., Rosselli M.S., Pirola C.J. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009, 50:2111-2116.
13. Rotman Y., Koh C., Zmuda J.M., Kleiner D.E., Liang T.J. NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894-903.
14. Devries M.C., Samjoo I.A., Hamadeh M.J., Tarnopolsky M.A. Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and women. Obes (Silver Spring) 2008, 16:2281-2288.
15. Higgins M., Province M., Heiss G., et al. NHLBI Family Heart Study: objectives and design. Am J Epidemiol 1996, 143:1219-1228.
16. Carr J.J., Nelson J.C., Wong N.D., et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 2005, 234:35-43.
17. Giannini E.G., Testa R., Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005, 172:367-379.
18. Kraja A.T., Vaidya D., Pankow J.S., et al. A bivariate genomewide approach to metabolic syndrome: STAMPEED consortium. Diabetes 2011, 60:1329-1339.
19. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D. Principal components analysis corrects for stratification in genomewide association studies. Nat Genet 2006, 38:904-909.
20. Province M.A., Borecki I.B. A correlated meta-analysis strategy for data mining "OMIC" scans 2013, PSB, Online Proceedings on press:. http://psb.stanford.edu/psb-online/proceedings/psb13/.
21. Borecki I.B., Province M.A. Genetic and genomic discovery using family studies. Circulation 2008, 118:1057-1063.
22. Pruim R.J., Welch R.P., Sanna S., et al. LocusZoom: regional visualization of genomewide association scan results. Bioinformatics 2010, 26:2336-2337.
23. Browman D.T., Resek M.E., Zajchowski L.D., Robbins S.M. Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci 2006, 119:3149-3160.
24. Calder P.C., Yaqoob P. Lipid rafts-composition, characterization, and controversies. J Nutr 2007, 137:545-547.
25. Li N., Huang X., Zhao Z., Chen G., Zhang W., Cao X. Identification and characterization of a novel gene KE04 differentially expressed by activated human dendritic cells. Biochem Biophys Res Commun 2000, 279:487-493.
26. Nseir W., Shalata A., Marmor A., Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011, 56:3439-3449.
27. Malaguarnera M., Di Rosa M., Nicoletti F., Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009, 87:679-695.
28. Flowers M.T., Ntambi J.M. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol 2008, 19:248-256.
29. Kotronen A., Seppänen-Laakso T., Westerbacka J., et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009, 58:203-208.
30. Stefan N., Peter A., Cegan A., et al. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008, 51:648-656.
31. Flowers M.T., Keller M.P., Choi Y., et al. Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol Genomics 2008, 33:361-372.
32. Ciba I., Widhalm K. The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. Acta Paediatr 2007, 96:109-112.